TITLE

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

AUTHOR(S)
Oyekunle, Anthony; Klyuchnikov, Evgeny; Ocheni, Sunday; Kröger, Nicolaus; Zander, Axel R.; Baccarani, Michele; Bacher, Ulrike
PUB. DATE
June 2011
SOURCE
Acta Haematologica;2011, Vol. 126 Issue 1, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic phase (CP) has declined rapidly, as allogeneic HSCT in CP is now performed in these patients only in case of failure or intolerance of TKIs. Second, those CML patients who undergo allogeneic HSCT represent a selection of high-risk patients due to more advanced disease with high rates of accelerated or blast phase (being associated with an increased relapse risk), advanced age and relevant co-morbidities. Efforts at meeting these special challenges are being developed: treatment with TKIs aims to improve the pre-transplant remission status before HSCT. Dose-reduced conditioning protocols were introduced to decrease transplant-related mortality in patients with co-morbidities or older age. In the post-transplant period, TKIs may be administered for prophylaxis and for treatment of post-transplant relapse. Still, the outcome of patients in advanced CML phases remains guarded, and requires an improvement in current transplant strategies. Copyright © 2011 S. Karger AG, Basel
ACCESSION #
62013496

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics